Skip to main
THC

Tenet Healthcare (THC) Stock Forecast & Price Target

Tenet Healthcare (THC) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 33%
Buy 60%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Tenet Healthcare reported a strong performance in the third quarter, achieving consolidated net operating revenue of $5.3 billion and an adjusted EBITDA of $1.1 billion, reflecting a 12% year-over-year growth and a 20.8% margin. The company's hospital segment displayed positive trends with a 1.4% increase in adjusted admissions and a 5.9% rise in revenue per adjusted admission, aided by a favorable payor mix and high-acuity cases, which contributed to an improvement in margins. Management has raised revenue guidance, indicating solid operational performance and signaling potential for long-term revenue growth, bolstered by a successful turnaround strategy and strong demand in both hospital and outpatient service segments.

Bears say

The financial outlook for Tenet Healthcare appears negative due to several fundamental concerns, including a disappointing EBITDA increase that was significantly lower than competitors HCA and UHS. Additionally, the company faces risks associated with high exposure to government-sponsored reimbursement programs, a leveraged balance sheet, and geographic concentration that may lead to increased operational volatility. These challenges, coupled with potential labor shortages and shifts in payer mix, raise substantial concerns regarding Tenet's ability to sustain robust financial performance moving forward.

Tenet Healthcare (THC) has been analyzed by 15 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 60% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tenet Healthcare and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tenet Healthcare (THC) Forecast

Analysts have given Tenet Healthcare (THC) a Buy based on their latest research and market trends.

According to 15 analysts, Tenet Healthcare (THC) has a Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $230.13, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $230.13, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tenet Healthcare (THC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.